Ovarian and endometrial function during hormonal contraception

Human Reproduction

Volumn 16, Issue 7, 2001, Pages 1527-1535

  Baird, D T ^a   Collins, J ^a   Cooke, I ^a   Glasier, A ^a   Jacobs, H S ^a   La Vecchia, C ^a   Stock, G ^a   Vercellini, P ^a   Cohen, J ^a   Crosignani, P G ^a   Diczfalusy, E ^a   Evers, J L H ^a   Skouby, S ^a   Tarlatzis, B ^a   Rubin, B L ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Cancer; Endometrial function; Oral contraceptives; Ovarian function

Indexed keywords

CONTRACEPTIVE AGENT; CYPROTERONE ACETATE; DANAZOL; DESOGESTREL PLUS ETHINYLESTRADIOL; ESTROGEN; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS LEVONORGESTREL; ETHINYLESTRADIOL PLUS NORETHISTERONE; FOLLITROPIN; GESTAGEN; GESTODENE; GONADORELIN DERIVATIVE; LEVONORGESTREL; LUTEINIZING HORMONE; MEFENAMIC ACID; MESTRANOL; MESTRANOL PLUS NORETHISTERONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; NORETHISTERONE; ORAL CONTRACEPTIVE AGENT; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE;

AMENORRHEA; CANCER RISK; CARBOHYDRATE METABOLISM; CARCINOGENESIS; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG COST; DRUG EFFECT; DRUG INDICATION; ENDOMETRIOSIS; ENDOMETRIUM; ENDOMETRIUM ATROPHY; ENDOMETRIUM CARCINOMA; FOLLITROPIN RELEASE; GYNECOLOGIC SURGERY; HORMONAL CONTRACEPTION; HORMONE INHIBITION; HUMAN; INCIDENCE; LIPID METABOLISM; LONG TERM CARE; META ANALYSIS; OVARY CYCLE; OVARY CYST; OVARY FOLLICLE DEVELOPMENT; OVARY FUNCTION; OVARY POLYCYSTIC DISEASE; OVARY TERATOMA; OVULATION INHIBITION; PATIENT COMPLIANCE; PELVIS PAIN SYNDROME; PRESCRIPTION; PROTECTION; QUALITY OF LIFE; RISK BENEFIT ANALYSIS; SMOKING; TESTOSTERONE RELEASE; TUMOR VOLUME; UTERUS BLEEDING; UTERUS FUNCTION; VAGINA BLEEDING;

FALLOPIA;

EID: 0034940482     PISSN: 02681161     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (82)

1. Multifollicular ovaries: Clinical and endocrine features and response to pulsatile gonadotropin releasing hormone
2. Comparative profiles of reliability, cycle control and side effects of two oral contraceptive formulations containing 150 μg desogestrel and either 30 or 20 μg ethinyl-oestradiol
3. Endometrial histology during use of a low-dose estrogen-desogestrel oral contraceptive with a reduced hormone-free interval
4. Danazol for heavy menstrual bleeding
5. The association between vaginal bleeding patterns and reasons for discontinuation of contraceptive use
6. A case-control study of benign ovarian tumours
7. Oral contraceptive use and benign gynecologic conditions
8. Management of abnormal uterine bleeding
9. The effects on ovarian activity of a monophasic oral contraceptive with 100 μg levonorgestrel and 20 μg ethinyl estradiol
10. Antifibrinolytics for heavy menstrual bleeding
11. Treating menorrhagia in primary care: An overview of drug trials and a survey of prescribing practice
12. Ovarian activity during regular oral contraceptive use
13. Pituitary and ovarian function in women on continuous low dose progestogens: Effects of chormadinone acetate and norethisterone
14. Ovulatory potential of preovulatory size follicles during oral contraceptive treatment
15. Omitting the first oral contraceptive pills of the cycles does not automatically lead to ovulation
16. The second-look laparoscopy for evaluation of the result of medical treatment of endometriosis should not be performed during ovarian suppression
17. Effects of long-term administration of an oral contraceptive containing ethinylestradiol and cyproterone acetate on lipid metabolism in women with polycystic ovary syndrome
18. Pooled analysis of 3 European case-control studies of epithelial ovarian cancer: III. Oral contraceptive use
19. Bleeding arising from the use of exogenous steroids
20. Randomised trial of 2 hormonal and 2 prostaglandin-inhibiting agents in women with a complaint of menorrhagia
21. Use of multiphasic oral contraceptives and hospitalizations of women with functional ovarian cysts in the United States
22. Ovulation and follicular development associated with three low-dose oral contraceptives: A randomized controlled trial
23. The estimated effect of oral contraceptive use on the cumulative risk of epithelial ovarian cancer
24. Estroprogestin vs. gonadotrophin agonists plus estroprogestins in the treatment of endometriosis-related pelvic pain: A randomized trial
25. Correlation of ultrasonic and endocrinologic assessment of human follicular development
26. Changes in vascular basement membrane in the endometrium of Norplant users
27. Progestogens versus oestrogens and progestogens for irregular uterine bleeding associated with anovulation
28. Functional ovarian cysts in relation to the use of monophasic and triphasic oral contraceptives
29. Ultrasound evaluation of ovarian activity under oral contraceptives
30. Monographs on the evaluation of carcinogenic risks to humans
31. Oral contraceptive pills for heavy menstrual bleeding
32. Comparison of ovarian follicular activity during treatment with a monthly injectable contraceptive and a low-dose oral contraceptive
33. Effects of ethinyl estradiol combined with desogestrel and cyproterone acetate on glucose tolerance and insulin response to an oral glucose load: A one-year randomized, prospective, comparative trial
34. Ovarian follicles during oral contraceptive cycles: Their potential for ovulation
35. Extending the duration of the pill-free interval during combined oral contraception
36. Ovarian activity in women taking an oral contraceptive containing 20 μg ethinyl oestradiol and 150 μg desorgestrel: Effects of low dose oestrogen doses during the hormone-free interval
37. Endocrinological effects of oral contraceptives
38. Oral contraceptives and ovarian cancer
39. Oral contraceptives and cancer. A review of the evidence
40. Cancer mortality in Europe: Effects of age, cohort of birth and period of death
41. Open randomised study of use of levonorgestrel releasing intrauterine system as alternative to hysterectomy
42. Hormonal effects of the 300 μg norethisterone (NET) minipill
43. Oral contraceptive type and functional ovarian cysts
44. Nonsteroidal anti-inflammatory drugs for heavy menstrual bleeding
45. Progesterone-progestogen releasing intrauterine system versus other placebo or any other medication for heavy menstrual bleeding
46. Cyclical progestogens for heavy menstrual bleeding
47. Oral contraceptives and the risk of endometrial cancer
48. Effects of cyproterone acetate (CPA) on serum lipoproteins when administered alone and in combination with ethinyl estradiol (ethinyl oestradiol)
49. Acceptability of an oral contraceptive that reduces the frequency of menstruation: The tricycle pill regimen
50. Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: A randomized study
51. Occurrence and function of corpora lutea during different forms of oral contraception
52. Oral contraceptives and fatal pulmonary embolism
53. Mortality of women with polycystic ovary syndrome at long-term follow-up
54. Oral contraceptives and cycle control: A critical review of the literature
55. A case-control study of oral contraceptive use and invasive epithelial ovarian cancer
56. Smoking and cycle control among oral contraceptive users
57. The role of progestogens in the hormonal control in fertility
58. Effects of a 1-year treatment with a low-dose combined oral contraceptive containing ethinyl estradiol and cyproterone acetate on glucose and insulin metabolism
59. The effects of cyproterone acetate and ethinyl oestradiol on carbohydrate metabolism
60. The effects of deliberate omission of Trinordiol® or Microgynon® on the hypothalamic-pituitary-ovarian axis
61. Pre-operative endometrial thinning agents before hysteroscopic surgery for heavy menstrual bleeding
62. Hormonal treatment of functional ovarian cysts: A randomized, prospective study
63. Serum luteinizing and follicle stimulating hormone levels during sequential and non-sequential contraceptive treatment of eugonadal women
64. Ultrasound demonstration of increased frequency of functional ovarian cysts using progestogen-only oral contraception
65. The influence of the dose of ethinylestradiol in oral contraceptives on follicle growth
66. Cycle control with oral contraceptives: A review of the literature
67. Expectant management of functional ovarian cysts: An alternative to hormonal therapy
68. Effects of seven low-dose combined oral contraceptives on sex hormone binding globulin, corticosteroid binding globulin, total and free testosterone
69. Activity of the pituitary-ovarian axis in the pill-free interval during use of low-dose combined oral contraceptive
70. A gonadotropin releasing hormone agonist versus a low-dose oral contraceptives for pelvic pain associated with endometriosis
71. Depot medroxyprogesterone acetate versus an oral contraceptive combined with very-low-dose danazol for long term treatment of pelvic pain associated with endometriosis
72. Progestins for symptomatic endometriosis: A critical analysis of the evidence
73. Surgical management of endometriosis
74. Ovarian neoplasms, functional ovarian cysts, and oral contraceptives
75. Recency, duration, and progestin content of oral contraceptives in relation to the incidence of endometrial cancer
76. Use of oral contraceptives and endometrial cancer risk (Sweden)
77. Benign cysts in England and Wales and the United States
78. Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: A retrospective cohort study
79. Paradoxical effects of the anti-androgen cyproterone acetate on lipid and lipoprotein metabolism